As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Zanubrutinib for treating Waldenström macroglobulinemia and mantle cell lymphoma.
This review discusses dosage and administration, efficacy and safety data and major studies featuring Zanubrutinib. It also provides commentary and recommendations from Professor Stephen Opat, haematologist and founder of the Australasian Lymphoma and Related Diseases Registry.
Please login below to download this issue (PDF)